Optimizing Anti-HER2 Therapy in early breast cancer: updates from the KRISTINE trial

首页> 外文期刊>Progress in Artificial Intelligence >Optimizing Anti-HER2 Therapy in early breast cancer: updates from the KRISTINE trial

【24h】

Optimizing Anti-HER2 Therapy in early breast cancer: updates from the KRISTINE trial

机译：优化早期乳腺癌的抗HER2疗法：克里斯汀试验的更新

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Progress in Artificial Intelligence》 |2020年第2期|共6页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类计算技术、计算机技术;
关键词

相似文献

外文文献
中文文献
专利

1. Optimizing Anti-HER2 Therapy in early breast cancer: updates from the KRISTINE trial [J] . Progress in Artificial Intelligence . 2020,第2期

机译：优化早期乳腺癌的抗HER2疗法：克里斯汀试验的更新
2. Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial [J] . N. Masuda, M. Toi, N. Yamamoto, Breast cancer . 2018,第4期

机译：曲妥珠单抗，拉帕替尼和紫杉醇新辅助疗法联合或不联合抗HER2治疗以及激素治疗对HER2阳性原发性乳腺癌的疗效和安全性：随机，五臂，多中心，开放标签期二审
3. Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials [J] . Cunfu Li, Aizhai Xiang, Xianzhi Chen, OncoTargets and therapy . 2017,第1期

机译：优化贝伐单抗作为人类表皮生长因子受体2（HER2）阴性晚期乳腺癌的一线治疗方法：已发表随机试验的最新荟萃分析
4. Deformable image registration as a tool to improve survival prediction after neoadjuvant chemotherapy for breast cancer: Results from the ACRIN 6657/I-SPY-1 trial [C] . Nariman Jahani, Eric Cohen, Meng-Kang Hsieh, SPIE Medical Imaging Conference . 2018

机译：可变形图像配准作为改善乳腺癌新辅助化疗后生存预测的工具：ACRIN 6657 / I-SPY-1试验的结果
5. Supportive Care for Patients with Breast Cancer by Using an Interactive App During Neoadjuvant Chemotherapy: A Randomized Controlled Trial [D] . Fjell, Maria. 2021

机译：通过在Neoadjuvant化疗期间使用互动性应用的乳腺癌患者的支持性护理：随机对照试验
6. Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials [O] . Cunfu Li, Aizhai Xiang, Xianzhi Chen, 2017

机译：优化贝伐单抗作为人类表皮生长因子受体2（HER2）阴性晚期乳腺癌的一线治疗方法：已发表随机试验的最新荟萃分析
7. Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials [O] . Cunfu Li, Aizhai Xiang, Xianzhi Chen, 2017

机译：优化人表皮生长因子受体2（HER2） - 儿童晚期乳腺癌的一线治疗贝伐单抗的治疗：发表随机试验的更新的荟萃分析
8. Anti-HER2/Toxin Expressing Lymphocytes for Breast Cancer Therapy [R] . Strube, R. 2001

机译：用于乳腺癌治疗的抗HER2 /毒素表达淋巴细胞

Optimizing Anti-HER2 Therapy in early breast cancer: updates from the KRISTINE trial

著录项

相似文献

相关主题

期刊订阅